Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
45 hedge funds and large institutions have $22.2M invested in Clearside Biomedical in 2020 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
13% more capital invested
Capital invested by funds: $19.6M → $22.2M (+$2.59M)
5% more funds holding
Funds holding: 43 → 45 (+2)
0.04% more ownership
Funds ownership: 1.71% → 1.75% (+0.04%)
99% less call options, than puts
Call options by funds: $14K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$822K |
| 2 |
Two Sigma Investments
New York
|
+$242K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$185K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$179K |
| 5 |
Millennium Management
New York
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$913K |
| 2 |
Morgan Stanley
New York
|
-$443K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$85.1K |
| 4 |
CG
Carmignac Gestion
Paris,
France
|
-$84.2K |
| 5 |
FAM
Fred Alger Management
New York
|
-$68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$7K | -256 | Closed |
|
CLSD Hedge Fund Activity: Q2 2020 in Review
45 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2020, worth a combined $22.2M — up 13% from $19.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLSD positions and 7 closed out — a net gain of 3 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $822K. The largest seller was Susquehanna International Group, cutting an estimated $913K.
- 45 institutional investors held Clearside Biomedical (CLSD) as of Q2 2020, up from 43 in Q1 2020.
- Funds reported $22.2M of Clearside Biomedical stock for Q2 2020, up 13% quarter-over-quarter.
- 10 funds opened new Clearside Biomedical positions in Q2 2020 and 7 closed out, a net change of +3 holders.
- The largest Clearside Biomedical buyer in Q2 2020 was Renaissance Technologies, an estimated $822K added.
- The largest Clearside Biomedical seller in Q2 2020 was Susquehanna International Group, an estimated $913K sold.
Based on aggregated 13F filings for Q2 2020.